GlobeNewswire by notified

KBC Group: KBC Bank Ireland (now Exicon DAC) to return its banking licence to the Central Bank of Ireland on 30 April 2024

Share

KBC Bank Ireland (renamed Exicon DAC on 8 February 2024) can confirm that it will return its banking licence to the Central Bank of Ireland on 30 April 2024, after having received approval from the Central Bank of Ireland and the European Central Bank. 

KBC Bank NV Dublin Branch staff will continue to be available to support any queries from customers. Customers retain their legal and regulatory protections. (More information for customers on https://www.kbc.com/en/kbc-ireland.html )

KBC Bank Ireland wishes to sincerely thank its  customers and stakeholders for their trust over the past decades and express its deep gratitude to all KBC Bank Ireland employees who have maintained the highest of standards in their work, providing continued support to customers and to each other while preparing the orderly exit.

Background

KBC Bank Ireland was established in 1973 as Irish Intercontinental Bank. In 1978, KBC Bank took a 75% interest in Irish Intercontinental Bank. KBC Bank acquired a full 100% shareholding in 1999.  On the 30th anniversary of KBC's majority ownership in 2008, the Bank was renamed KBC Bank Ireland plc.

Given the challenging operational context for European banks and after careful consideration, KBC Bank Ireland entered into a legally binding agreement with Bank of Ireland relating to the sale of substantially all of KBC Bank Ireland’s performing loan assets and its deposit book to Bank of Ireland Group on 22 October 2021. In addition, a small portfolio of non-performing mortgages (NPEs) was also acquired by Bank of Ireland as part of the transaction(link to press release)

KBC Bank Ireland closed the sale of substantially all of its assets and liabilities to Bank of Ireland on 3 February 2023 (link to press release) and started preparing the return of its banking licence to the Central Bank of Ireland.

As KBC Bank Ireland would no longer be operating in the Irish market, on 25 May 2023 KBC Bank Ireland and KBC Bank NV, acting through its branch in Ireland, agreed the transfer of any remaining accounts and servicing activity to KBC Bank NV Dublin Branch. On 13 September 2023 the Minister for Finance approved the Transfer. On 1 December 2023 KBC Bank Ireland completed the transfer agreement in respect of substantially all of its remaining assets and current and future liabilities to KBC Bank NV Dublin Branch which includes all unidentified and identified residual customer or regulatory claims or liabilities of the Bank. KBC Bank NV Dublin Branch is licenced by the National Bank of Belgium in Belgium and is regulated by the Central Bank of Ireland for conduct of business rules. On 8 February 2024 KBC Bank Ireland was renamed Exicon DAC.

For more information, please contact:

Kurt De Baenst, General Manager, Investor Relations, KBC Group
Tel. + 32 2 429 35 73  - IR4U@kbc.be

Viviane Huybrecht, General Manager, Corporate Communication/Spokesperson, KBC Group
Tel + 32 2 429 85 45  -  pressofficekbc@kbc.be

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

Nokia Corporation: Repurchase of own shares on 07.05.20247.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 07 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 07.05.2024 Espoo, Finland – On 07 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL376,2023.48CEUX--BATE--AQEU--TQEX--Total376,2023.48 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye